176 related articles for article (PubMed ID: 17194595)
41. N-(arylacetyl)-biphenylalanines as potent VLA-4 antagonists.
Li B; de Laszlo SE; Kamenecka TM; Kopka IE; Durette PL; Lanza T; MacCoss M; Tong S; Mumford RA; McCauley ED; Van Riper G; Schmidt JA; Hagmann WK
Bioorg Med Chem Lett; 2002 Aug; 12(16):2141-4. PubMed ID: 12127523
[TBL] [Abstract][Full Text] [Related]
42. Substituted 3-amino biaryl propionic acids as potent VLA-4 antagonists.
Kopka IE; Lin LS; Mumford RA; Lanza T; Magriotis PA; Young D; DeLaszlo SE; MacCoss M; Mills SG; Van Riper G; McCauley E; Lyons K; Vincent S; Egger LA; Kidambi U; Stearns R; Colletti A; Teffera Y; Tong S; Owens K; Levorse D; Schmidt JA; Hagmann WK
Bioorg Med Chem Lett; 2002 Sep; 12(17):2415-8. PubMed ID: 12161146
[TBL] [Abstract][Full Text] [Related]
43. Identification of N-acyl 4-(5-pyrimidine-2,4-dionyl)phenylalanine derivatives and their orally active prodrug esters as dual-acting alpha4-beta1 and alpha4-beta7 receptor antagonists.
Sidduri A; Tilley JW; Lou J; Tare N; Cavallo G; Frank K; Pamidimukkala A; Choi DS; Gerber L; Railkar A; Renzetti L
Bioorg Med Chem Lett; 2013 Feb; 23(4):1026-31. PubMed ID: 23312474
[TBL] [Abstract][Full Text] [Related]
44. Identification of N-acyl 4-(3-pyridonyl)phenylalanine derivatives and their orally active prodrug esters as dual acting α4β1 and α4β7 receptor antagonists.
Tilley JW; Sidduri A; Lou J; Kaplan G; Tare N; Cavallo G; Frank K; Pamidimukkala A; Choi DS; Gerber L; Railkar A; Renzetti L
Bioorg Med Chem Lett; 2013 Feb; 23(4):1036-40. PubMed ID: 23312471
[TBL] [Abstract][Full Text] [Related]
45. Structure-activity relationship studies of a series of peptidomimetic ligands for alpha(4) beta(1) integrin on Jurkat T-leukemia cells.
Liu R; Peng L; Han H; Lam KS
Biopolymers; 2006; 84(6):595-604. PubMed ID: 17041919
[TBL] [Abstract][Full Text] [Related]
46. Dehydrophenylalanine derivatives as VLA-4 integrin antagonists.
Porter JR; Archibald SC; Brown JA; Childs K; Critchley D; Head JC; Parton TA; Robinson MK; Shock A; Taylor RJ; Warrellow GJ
Bioorg Med Chem Lett; 2003 Mar; 13(5):805-8. PubMed ID: 12617895
[TBL] [Abstract][Full Text] [Related]
47. Synthesis of 2,5-thiazole butanoic acids as potent and selective alpha(v)beta3 integrin receptor antagonists with improved oral pharmacokinetic properties.
Wendt JA; Wu H; Stenmark HG; Boys ML; Downs VL; Penning TD; Chen BB; Wang Y; Duffin T; Finn MB; Keene JL; Engleman VW; Freeman SK; Hanneke ML; Shannon KE; Nickols MA; Steininger CN; Westlin M; Klover JA; Westlin W; Nickols GA; Russell MA
Bioorg Med Chem Lett; 2006 Feb; 16(4):845-9. PubMed ID: 16303301
[TBL] [Abstract][Full Text] [Related]
48. CVT-4325: a potent fatty acid oxidation inhibitor with favorable oral bioavailability.
Elzein E; Ibrahim P; Koltun DO; Rehder K; Shenk KD; Marquart TA; Jiang B; Li X; Natero R; Li Y; Nguyen M; Kerwar S; Chu N; Soohoo D; Hao J; Maydanik VY; Lustig DA; Zeng D; Leung K; Zablocki JA
Bioorg Med Chem Lett; 2004 Dec; 14(24):6017-21. PubMed ID: 15546720
[TBL] [Abstract][Full Text] [Related]
49. From pyrroles to 1-oxo-2,3,4,9-tetrahydro-1H-beta-carbolines: a new class of orally bioavailable mGluR1 antagonists.
Di Fabio R; Micheli F; Alvaro G; Cavanni P; Donati D; Gagliardi T; Fontana G; Giovannini R; Maffeis M; Mingardi A; Tranquillini ME; Vitulli G
Bioorg Med Chem Lett; 2007 Apr; 17(8):2254-9. PubMed ID: 17276684
[TBL] [Abstract][Full Text] [Related]
50. Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type 2 diabetes.
Xia Y; Chackalamannil S; Greenlee WJ; Jayne C; Neustadt B; Stamford A; Vaccaro H; Xu XL; Baker H; O'Neill K; Woods M; Hawes B; Kowalski T
Bioorg Med Chem Lett; 2011 Jun; 21(11):3290-6. PubMed ID: 21536438
[TBL] [Abstract][Full Text] [Related]
51. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J
Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
[TBL] [Abstract][Full Text] [Related]
52. Arylsulfonamide pyrimidines as VLA-4 antagonists.
Xu YZ; Konradi AW; Bard F; Dappen M; Dofiles L; Dreyer M; Gallager I; Garrido C; Krimm M; Liao Z; Messersmith E; Mutter L; Pleiss MA; Samant B; Semko CM; Smith J; Stappenbeck F; Stupi B; Vandervert C; Welch B; Wipke B; Yednock T
Bioorg Med Chem Lett; 2013 May; 23(10):3070-4. PubMed ID: 23562062
[TBL] [Abstract][Full Text] [Related]
53. Discovery of N-{N-[(3-cyanophenyl)sulfonyl]-4(R)-cyclobutylamino-(L)-prolyl}-4-[(3',5'-dichloroisonicotinoyl) amino]-(L)-phenylalanine (MK-0668), an extremely potent and orally active antagonist of very late antigen-4.
Lin LS; Lanza T; Jewell JP; Liu P; Jones C; Kieczykowski GR; Treonze K; Si Q; Manior S; Koo G; Tong X; Wang J; Schuelke A; Pivnichny J; Wang R; Raab C; Vincent S; Davies P; Maccoss M; Mumford RA; Hagmann WK
J Med Chem; 2009 Jun; 52(11):3449-52. PubMed ID: 19441819
[TBL] [Abstract][Full Text] [Related]
54. Discovery of a novel series of biphenyl benzoic acid derivatives as highly potent and selective human beta3 adrenergic receptor agonists with good oral bioavailability. Part II.
Imanishi M; Itou S; Washizuka K; Hamashima H; Nakajima Y; Araki T; Tomishima Y; Sakurai M; Matsui S; Imamura E; Ueshima K; Yamamoto T; Yamamoto N; Ishikawa H; Nakano K; Unami N; Hamada K; Matsumura Y; Takamura F; Hattori K
J Med Chem; 2008 Jul; 51(13):4002-20. PubMed ID: 18553954
[TBL] [Abstract][Full Text] [Related]
55. Pharmacological and pharmacokinetic characterization of 2-piperazine-alpha-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonists.
Chen C; Tucci FC; Jiang W; Tran JA; Fleck BA; Hoare SR; Wen J; Chen T; Johns M; Markison S; Foster AC; Marinkovic D; Chen CW; Arellano M; Harman J; Saunders J; Bozigian H; Marks D
Bioorg Med Chem; 2008 May; 16(10):5606-18. PubMed ID: 18417348
[TBL] [Abstract][Full Text] [Related]
56. Constraining the amide bond in N-sulfonylated dipeptide VLA-4 antagonists.
Chang LL; Yang GX; McCauley E; Mumford RA; Schmidt JA; Hagmann WK
Bioorg Med Chem Lett; 2008 Mar; 18(5):1688-91. PubMed ID: 18242984
[TBL] [Abstract][Full Text] [Related]
57. Substituted tetrahydrofuroyl-1-phenylalanine derivatives as potent and specific VLA-4 antagonists.
Doherty GA; Yang GX; Borges E; Chang LL; MacCoss M; Tong S; Kidambi U; Egger LA; McCauley E; Van Riper G; Mumford RA; Schmidt JA; Hagmann WK
Bioorg Med Chem Lett; 2002 Jun; 12(11):1501-5. PubMed ID: 12031329
[TBL] [Abstract][Full Text] [Related]
58. Discovery of diphenylcarbamate derivatives as highly potent and selective IP receptor agonists: orally active prostacyclin mimetics. Part 3.
Hattori K; Tanaka A; Okitsu O; Tabuchi S; Taniguchi K; Nishio M; Koyama S; Higaki M; Seki J; Sakane K
Bioorg Med Chem Lett; 2005 Jun; 15(12):3091-5. PubMed ID: 15914004
[TBL] [Abstract][Full Text] [Related]
59. N-aryl-prolyl-dipeptides as potent antagonists of VLA-4.
Kamenecka TM; Lanza T; de Laszlo SE; Li B; McCauley ED; Van Riper G; Egger LA; Kidambi U; Mumford RA; Tong S; MacCoss M; Schmidt JA; Hagmann WK
Bioorg Med Chem Lett; 2002 Aug; 12(16):2205-8. PubMed ID: 12127538
[TBL] [Abstract][Full Text] [Related]
60. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
Lee B; Shi L; Kassel DB; Asakawa T; Takeuchi K; Christopher RJ
Eur J Pharmacol; 2008 Jul; 589(1-3):306-14. PubMed ID: 18538760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
